TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25295646

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) up to 70 mg/day for 5 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-immediate release (MAS-IR) up to 45 mg/day for 5 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PBO) for 1 week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo washout for 3 weeks
Number of subjects: 24
Study: 25295805

Group type: EXPERIMENTAL
Intervention: Parental atopy
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Higher paternal education
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: More frequent house cleaning
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Keeping a pet at home during pregnancy
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Longer breast-feeding
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Maternal exposure to increased concentrations of particulate matter 10
Number of subjects: 501
Study: 25296268

Group type: EXPERIMENTAL
Intervention: Childhood-onset asthma
Number of subjects: 590

Group type: COMPARATOR
Intervention: Subjects without childhood-onset asthma
Number of subjects: 590
Study: 25296762

Group type: EXPERIMENTAL
Intervention: Moderate-SFA reduction (3.68-13.67 g)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-SFA reduction (>13.67 g)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-SFA reduction (<3.68 g)
Number of subjects: 60
Study: 25296772

Group type: EXPERIMENTAL
Intervention: Thrombophilia panel measured in previously treated patients with chronic immune thrombocytopenia enrolled in an eltrombopag trial.
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Presence of multiple baseline thrombophilia risk markers.
Number of subjects: 167
Study: 25297720

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir/lopinavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 0
Study: 25298356

Group type: EXPERIMENTAL
Intervention: AbsorbTM BVS 1.1 implantation
Number of subjects: 0
Study: 25298411

Group type: EXPERIMENTAL
Intervention: Short eyes (axial length <22.5 mm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Medium eyes (axial length 22.51-25.50 mm)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long eyes (axial length >25.52 mm)
Number of subjects: 8
Study: 25299251

Group type: EXPERIMENTAL
Intervention: Clinical management practices of dengue by physicians
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Knowledge of early signs of shock and warning signs for severe dengue
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Use of corticosteroids and prophylactic platelet transfusions
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Best treatment options for dengue patients with refractory shock
Number of subjects: 817
Study: 25299391

Group type: EXPERIMENTAL
Intervention: Mebendazole (MEB; 500 mg)
Number of subjects: 5830

Group type: COMPARATOR
Intervention: Albendazole (ALB; 400 mg)
Number of subjects: 5830
Study: 25300734

Group type: EXPERIMENTAL
Intervention: High fiber diet intervention
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: American Heart Association diet intervention
Number of subjects: 204
Study: 25301151

Group type: EXPERIMENTAL
Intervention: C-Pulse System
Number of subjects: 20
Study: 25301172

Group type: EXPERIMENTAL
Intervention: RRV-mediated CD/5-FC prodrug activator gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-FC
Number of subjects: 0
Study: 25301367

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (3 cigarettes in one hour)
Number of subjects: 0
Study: 25301708

Group type: EXPERIMENTAL
Intervention: XmAb5574 (MOR00208)
Number of subjects: 27
Study: 25301783

Group type: EXPERIMENTAL
Intervention: New risk score for one-year mortality developed from 12 independent predictors.
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: New risk score for one-year mortality with excellent discrimination (c-statistic=0.81).
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Risk score stratification for one-year mortality.
Number of subjects: 10568

Group type: EXPERIMENTAL
Intervention: Identification of high-risk patients using the risk score.
Number of subjects: 10568
Study: 25302057

Group type: EXPERIMENTAL
Intervention: Sports drink
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 8
Study: 25303490

Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG) 25 μg iv administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study: 25304008

Group type: EXPERIMENTAL
Intervention: Nadroparin 5700 IU subcutaneous (s.c.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nadroparin 2850 IU subcutaneous (s.c.)
Number of subjects: 35
Study: 25304129

Group type: EXPERIMENTAL
Intervention: Partial PPI responders
Number of subjects: 783

Group type: COMPARATOR
Intervention: Treatment-naïve patients
Number of subjects: 783

Group type: COMPARATOR
Intervention: Treatment-naïve patients after PPI therapy
Number of subjects: 783
Study: 25304161

Group type: EXPERIMENTAL
Intervention: Dual-innervated dorsal digital flap
Number of subjects: 73

Group type: COMPARATOR
Intervention: Single-innervated flap
Number of subjects: 73
Study: 25304476

Group type: EXPERIMENTAL
Intervention: Postoperative pain recorded at 24 hours, assessed at 8 weeks, 6 months, and 12 months using questionnaires of pain intensity and interference.
Number of subjects: 381
Study: 25304612

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 25304614

Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita
Number of subjects: 4

Group type: COMPARATOR
Intervention: Fanconi anemia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Diamond-Blackfan anemia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Shwachman-Diamond syndrome
Number of subjects: 4
Study: 25304641

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily (adjusted according to creatinine clearance and hemoglobin values) for 24 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin combination therapy
Number of subjects: 40
Study: 25304729

Group type: EXPERIMENTAL
Intervention: IFN-α therapy (3 MU 3 times weekly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nontreatment group
Number of subjects: 48
Study: 25304766

Group type: EXPERIMENTAL
Intervention: Core module (baseline, six, and 12 months)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Snapshot module (months three and nine)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Core module
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Comorbidities/Endophenotypes module
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Family Burden (Proband) module
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Family Burden (Partner) module
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Family Burden (Child) module
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Snapshot module (three months)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Core module (six months)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Snapshot module (nine months)
Number of subjects: 16789

Group type: EXPERIMENTAL
Intervention: Core module (12 months)
Number of subjects: 16789
Study: 25304853

Group type: EXPERIMENTAL
Intervention: Early aspirin therapy
Number of subjects: 14041
Study: 25305371

Group type: EXPERIMENTAL
Intervention: Contralateral cane use
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ipsilateral cane use
Number of subjects: 38

Group type: COMPARATOR
Intervention: No cane
Number of subjects: 38

Group type: COMPARATOR
Intervention: Contralateral cane use vs Ipsilateral cane use
Number of subjects: 38
Study: 25305705

Group type: EXPERIMENTAL
Intervention: Aliskiren (ALIS)
Number of subjects: 13433

Group type: EXPERIMENTAL
Intervention: ACE inhibitor/angiotensin receptor blocker (ACEI/ARB)
Number of subjects: 13433

Group type: EXPERIMENTAL
Intervention: Antihypertensive agent not affecting the renin angiotensin system (non-RAS)
Number of subjects: 13433

Group type: COMPARATOR
Intervention: All groups (ALIS, ACEI/ARB, non-RAS)
Number of subjects: 13433
Study: 25306425

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 11
Study: 25307045

Group type: EXPERIMENTAL
Intervention: SIAscopy
Number of subjects: 0
Study: 25307417

Group type: EXPERIMENTAL
Intervention: School-wide positive behavioral interventions and supports (PBIS)
Number of subjects: 0
Study: 25307711

Group type: EXPERIMENTAL
Intervention: Infusion of 5 ml/kg of Ringer's acetate intravenously for over 15 min
Number of subjects: 30
Study: 25308138

Group type: EXPERIMENTAL
Intervention: h-FABP above 6 μg/L
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: BNP > 100 pg/mL
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: cTnI-Ultra > 0.05 μg/L
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PESI low class I or II
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination of h-FABP with PESI
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: h-FABP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: PESI
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: cTnI-Ultra
Number of subjects: 132
Study: 25308921

Group type: EXPERIMENTAL
Intervention: Pro-C3
Number of subjects: 194

Group type: COMPARATOR
Intervention: C3M
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Baseline Pro-C3
Number of subjects: 194
Study: 25309090

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets, 4 tablets with 250 mL of water every 15 min, three times on the day of the procedure.
Number of subjects: 30
Study: 25310119

Group type: EXPERIMENTAL
Intervention: Mentor Mother program
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard-of-care, informal peer support
Number of subjects: 480
Study: 25310303

Group type: EXPERIMENTAL
Intervention: T-cell-depleted haploidentical SCT (HHCT)
Number of subjects: 28
Study: 25311774

Group type: EXPERIMENTAL
Intervention: Abdominoperineal excision (APE)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Preoperative information regarding sexual dysfunction
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sexual activity
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Thoughts about sex
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Satisfaction with sexual function
Number of subjects: 108
Study: 25311835

Group type: EXPERIMENTAL
Intervention: Later bedtime
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Later wake time
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Later midpoint of sleep
Number of subjects: 22
Study: 25312446

Group type: EXPERIMENTAL
Intervention: Antipsychotic monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotic polytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Add-on therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total disease-related cost per patient per annum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospitalisations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nursing home stays
Number of subjects: 0
Study: 25312589

Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 81
Study: 25313095

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg every 2 weeks (with dose adjustments for weight)
Number of subjects: 181
Study: 25313914

Group type: EXPERIMENTAL
Intervention: 25 μg recombinant-human chorionic gonadotropin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (normal women)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PCOS women with normal 17-OHP responses
Number of subjects: 36
Study: 25314069

Group type: EXPERIMENTAL
Intervention: α-tocopherol (50 mg/day)
Number of subjects: 29105

Group type: EXPERIMENTAL
Intervention: β-carotene (20 mg/day)
Number of subjects: 29105

Group type: EXPERIMENTAL
Intervention: Both α-tocopherol and β-carotene
Number of subjects: 29105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29105
Study: 25314291

Group type: EXPERIMENTAL
Intervention: CT-carriers (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CC-carriers (n=20)
Number of subjects: 40
Study: 25314641

Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg once daily plus carboplatin/paclitaxel
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo plus carboplatin/paclitaxel
Number of subjects: 18
Study: 25315074

Group type: EXPERIMENTAL
Intervention: (90)Y ibritumomab tiuxetan (Zevalin)
Number of subjects: 16
Study: 25315258

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice daily
Number of subjects: 60
Study: 25315502

Group type: EXPERIMENTAL
Intervention: Surgically treated patients (two-year weight loss = 16%)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Medically managed patients (two-year weight loss = 3%)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 500
Study: 25315670

Group type: EXPERIMENTAL
Intervention: Naked oat combined with a structured dietary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25316260

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 76304

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 76304

Group type: COMPARATOR
Intervention: Never smokers with passive smoking exposure
Number of subjects: 76304

Group type: COMPARATOR
Intervention: Never smokers with adult home passive smoking exposure ≥30 years
Number of subjects: 76304
Study: 25316347

Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-peripheral artery disease controls
Number of subjects: 31
Study: 25316810

Group type: EXPERIMENTAL
Intervention: MRD(-) cases at 12 months
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: MRD(-) cases at 24 months
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: CR/PCR(-) cases
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: PR/PCR(-) cases
Number of subjects: 415
Study: 25317092

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Demographics and anthropometrics
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Day of the week and school break
Number of subjects: 143
Study: 25317365

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Duloxetine (both dosages)
Number of subjects: 336
Study: 25317759

Group type: EXPERIMENTAL
Intervention: Outpatient antimicrobial stewardship intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25317870

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor-modified T cells (CTL019)
Number of subjects: 30
Study: 25318437

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg IV on Days 1, 8, 15, and 22 of a 28 day cycle and Bevacizumab 10 mg/kg IV on Days 1 and 15 of the cycle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Temsirolimus and Bevacizumab
Number of subjects: 28
Study: 25319501

Group type: EXPERIMENTAL
Intervention: CD19-CAR T cells (1×10^6 CAR-transduced T cells per kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CD19-CAR T cells
Number of subjects: 21
Study: 25320340

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily)
Number of subjects: 48
Study: 25320355

Group type: EXPERIMENTAL
Intervention: Ridaforolimus (10-40 mg/day every day × 5/week) and dalotuzumab (10 mg/kg/week or 7.5 mg/kg/every other week)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ridaforolimus and dalotuzumab combination
Number of subjects: 87
Study: 25320535

Group type: EXPERIMENTAL
Intervention: SMART (66 Gy/30 F to PTV66 and 54 Gy/30 F to PTV54)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 10
Study: 25320633

Group type: EXPERIMENTAL
Intervention: Maraviroc and Raltegravir
Number of subjects: 22

Group type: COMPARATOR
Intervention: Truvada® plus Kaletra® (control)
Number of subjects: 22
Study: 25322359

Group type: EXPERIMENTAL
Intervention: Frozen fecal microbiota transplantation (FMT) capsules, 15 capsules administered on 2 consecutive days.
Number of subjects: 20
Study: 25322531

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHG) in 70% alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Povidone iodine
Number of subjects: 0
Study: 25323055

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 363
Study: 25323230

Group type: EXPERIMENTAL
Intervention: Eosinophilic inflammation assessment in COPD patients
Number of subjects: 0
Study: 25323247

Group type: EXPERIMENTAL
Intervention: Evaluation by oncologist
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ICU admission
Number of subjects: 140

Group type: COMPARATOR
Intervention: Performance status ⩽2
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nonprogressive malignancy
Number of subjects: 140

Group type: COMPARATOR
Intervention: No explicit refusal of ICU admission
Number of subjects: 140

Group type: COMPARATOR
Intervention: Initial ward other than lung cancer unit
Number of subjects: 140

Group type: COMPARATOR
Intervention: Available medical ICU bed
Number of subjects: 140
Study: 25323764

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) therapy at a mean dose of 0.053 mg/kg/day over 3 years
Number of subjects: 19

Group type: COMPARATOR
Intervention: historical cohort of untreated HCH children
Number of subjects: 19
Study: 25324042

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 100
Study: 25324973

Group type: EXPERIMENTAL
Intervention: 350 ng aviscumine twice weekly by subcutaneous injection until progression
Number of subjects: 32
Study: 25325296

Group type: EXPERIMENTAL
Intervention: HIV prevention services package including condom and lubricant choices, risk-reduction counseling, couples HIV testing and counseling, pre-exposure prophylaxis (PrEP), non-occupational post-exposure prophylaxis.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Training for health care providers to facilitate clinically and culturally competent care for MSM.
Number of subjects: 200
Study: 25325480

Group type: EXPERIMENTAL
Intervention: Abnormal breathing events defined by an apnea-hypopnea index (AHI) > 15
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Abnormal breathing events defined by an apnea-hypopnea index (AHI) > 30
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Chronic hypoxemia defined as cumulative peripheral oxygen saturation (SpO2) < 90% or minimal SpO2
Number of subjects: 559
Study: 25325684

Group type: EXPERIMENTAL
Intervention: Needle-based confocal laser endomicroscopy (nCLE) combined with endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 31
Study: 25326006

Group type: EXPERIMENTAL
Intervention: First hospitalization for cardiovascular (CV) reasons
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: First hospitalization for non-cardiovascular (non-CV) reasons
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Not hospitalized
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: 30-day survivors of CV hospitalization
Number of subjects: 7599

Group type: EXPERIMENTAL
Intervention: 30-day survivors of non-CV hospitalization
Number of subjects: 7599
Study: 25326543

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 54
Study: 25327505

Group type: EXPERIMENTAL
Intervention: Amikacin (20 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amikacin (25 mg/kg)
Number of subjects: 60
Study: 25328681

Group type: EXPERIMENTAL
Intervention: PROSTVAC immunotherapy
Number of subjects: 100
Study: 25328711

Group type: EXPERIMENTAL
Intervention: Melatonin 6mg oral for 3 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25329038

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated SBP ≥140 mm Hg)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated SBP ≥140 mm Hg)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated DBP ≥90 mm Hg)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated DBP ≥90 mm Hg)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg (elevated DBP)
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg (elevated DBP)
Number of subjects: 2313
Study: 25329562

Group type: EXPERIMENTAL
Intervention: Obeticholic acid 25 mg daily for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (bile acid sequestrants discontinued)
Number of subjects: 28
Study: 25329821

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg as carbonate)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1675
Study: 25330000

Group type: EXPERIMENTAL
Intervention: Cluster 1 dietary pattern (least healthy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cluster 3 dietary pattern (healthiest)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cluster 2 dietary pattern (intermediate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Healthier dietary pattern
Number of subjects: 45
Study: 25330463

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg QD sc for 12 weeks
Number of subjects: 36